The entryway at #ASH19 Each ASH annual meeting has its own ‘flavor’ and emphasis regarding myeloma. I’ve been to several and remember the excitement of ASH2015 after our unprecedented elotuzumab, daratumumab, Ninlaro, “November to Remember.” Last year the emphasis was on early immunotherapy with BiTEs, CAR-T, and ADCs (antibody drug conjugates). This year ASH2019 was […]